CD163 and plasma cell myeloma: We evaluated the levels of sCD163 in serum and observed no differences between healthy donors and CRC patients, which is in agreement with studies on ovarian cancer [13], melanoma [14], and multiple myeloma [17], but in contrast with a study on hepatocellular carcinoma [15] and another study in CRC patients by Ding et al. [16].